Buchumschlag

Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification

Circulating soluble urokinase receptor (suPAR) was recently identified as one of the causes responsible for native and recurrent focal segmental glomerulosclerosis (FSGS) through overactivation of podocyte β3 integrin. Here, we discuss the management of a patient with very high suPAR serum levels an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Morath, Christian (VerfasserIn) , Wei, Changli (VerfasserIn) , Macher-Göppinger, Stephan (VerfasserIn) , Schwenger, Vedat (VerfasserIn) , Zeier, Martin (VerfasserIn) , Reiser, Jochen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: Mar 1, 2013
In: American journal of therapeutics
Year: 2013, Jahrgang: 20, Heft: 2, Pages: 226-229
ISSN:1536-3686
DOI:10.1097/MJT.0b013e3182811aca
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/MJT.0b013e3182811aca
Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/americantherapeutics/Abstract/2013/03000/Management_of_Severe_Recurrent_Focal_Segmental.15.aspx
Volltext
Verfasserangaben:Morath, Christian MD; Wei, Changli MD, PhD; Macher-Goeppinger, Stephan MD; Schwenger, Vedat MD; Zeier, Martin MD; Reiser, Jochen MD, PhD
Beschreibung
Zusammenfassung:Circulating soluble urokinase receptor (suPAR) was recently identified as one of the causes responsible for native and recurrent focal segmental glomerulosclerosis (FSGS) through overactivation of podocyte β3 integrin. Here, we discuss the management of a patient with very high suPAR serum levels and FSGS recurrence. The suPAR reduction using plasmapheresis and immunoadsorption allowed for lowering of suPAR and reduced podocyte β3 integrin activation and proteinuria. The patient is successfully weaned to bimonthly suPAR removal treatments with improved renal parameters. In summary, we provide an approach for the successful management of severe recurrent FSGS using available therapies with biomarker guidance.
Beschreibung:Gesehen am 07.06.2021
Beschreibung:Online Resource
ISSN:1536-3686
DOI:10.1097/MJT.0b013e3182811aca

Ähnliche Einträge